These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 32926272)

  • 81. The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19.
    Shi X; Chen M; Zhang Y
    Mol Biol Rep; 2021 Feb; 48(2):1763-1771. PubMed ID: 33483864
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
    Albini A; Di Guardo G; Noonan DM; Lombardo M
    Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Rationale for targeting complement in COVID-19.
    Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
    EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
    Li SR; Tang ZJ; Li ZH; Liu X
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
    Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications.
    Ma Z; Yang KY; Huang Y; Lui KO
    J Mol Cell Cardiol; 2022 Mar; 164():69-82. PubMed ID: 34838588
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cardiovascular Complications in Coronavirus Disease 2019-Pathogenesis and Management.
    Restrepo MI; Marin-Corral J; Rodriguez JJ; Restrepo V; Cavallazzi R
    Semin Respir Crit Care Med; 2023 Feb; 44(1):21-34. PubMed ID: 36646083
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
    Zemlin AE; Wiese OJ
    Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Commonalities Between COVID-19 and Radiation Injury.
    Rios CI; Cassatt DR; Hollingsworth BA; Satyamitra MM; Tadesse YS; Taliaferro LP; Winters TA; DiCarlo AL
    Radiat Res; 2021 Jan; 195(1):1-24. PubMed ID: 33064832
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.
    Vitiello A; Ferrara F
    Life Sci; 2020 Dec; 262():118510. PubMed ID: 32991879
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.
    Higashikuni Y; Liu W; Obana T; Sata M
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769508
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cardiovascular complications of COVID-19.
    Farshidfar F; Koleini N; Ardehali H
    JCI Insight; 2021 Jul; 6(13):. PubMed ID: 34061779
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
    Talasaz AH; Kakavand H; Van Tassell B; Aghakouchakzadeh M; Sadeghipour P; Dunn S; Geraiely B
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):249-259. PubMed ID: 32671601
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Impact of COVID-19 on Cardiovascular Disease.
    Vosko I; Zirlik A; Bugger H
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851722
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread.
    Alsaidan AA; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Alsayed KA; Saad HM; Batiha GE
    Immun Inflamm Dis; 2023 Mar; 11(3):e798. PubMed ID: 36988260
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?
    Pivonello R; Auriemma RS; Pivonello C; Isidori AM; Corona G; Colao A; Millar RP
    Neuroendocrinology; 2021; 111(11):1066-1085. PubMed ID: 33242856
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19.
    Saghafi N; Rezaee SA; Momtazi-Borojeni AA; Tavasolian F; Sathyapalan T; Abdollahi E; Sahebkar A
    Life Sci; 2022 Apr; 294():120392. PubMed ID: 35149115
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pathomechanisms of SARS-CoV-2 infection and development of atherosclerosis in patients with COVID-19: A review.
    Gospodarczyk AZ; Wojciechowska C; Marczewski KP; Gospodarczyk NJ; Zalejska-Fiolka J
    Medicine (Baltimore); 2022 Dec; 101(49):e31540. PubMed ID: 36626452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.